CAMCEVI ETM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CAMCEVI ETM (CAMCEVI ETM).
Leuprolide is a GnRH agonist that inhibits pituitary gonadotropin secretion, leading to suppression of testicular and ovarian steroidogenesis.
| Metabolism | Metabolized primarily by peptide hydrolysis; not a substrate for CYP450 enzymes. |
| Excretion | Following subcutaneous injection, CAMCEVI (leuprolide) is primarily eliminated via renal excretion. Approximately 90% of a leuprolide dose is recovered in urine as parent drug and metabolite fractions, with 5% excreted in feces via biliary elimination. |
| Half-life | The terminal elimination half-life of CAMCEVI after subcutaneous administration is approximately 3 hours. This short half-life reflects rapid clearance; however, the clinical duration of action is prolonged due to the depot formulation providing continuous release over 6 months. |
| Protein binding | Leuprolide is approximately 45% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution of leuprolide is approximately 0.3 L/kg, indicating limited extravascular distribution consistent with a polar peptide that does not extensively penetrate tissues. |
| Bioavailability | Subcutaneous injection: 100% bioavailability (complete absorption from the depot formulation). Intravenous administration is not indicated; oral bioavailability is negligible (<1%) due to peptide degradation. |
| Onset of Action | Subcutaneous injection: Initial testosterone suppression begins within 2-4 weeks. Maximal suppression (castrate levels <50 ng/dL) is achieved by 4 weeks after the first dose. |
| Duration of Action | A single subcutaneous injection of CAMCEVI provides therapeutic suppression of testosterone for 6 months. Clinical guidelines recommend dosing every 6 months to maintain castrate levels. Testosterone returns to baseline after discontinuation as the depot is cleared. |
| Molecular Weight | 1209.4 Da |
21 mg subcutaneously once every 6 months.
| Dosage form | EMULSION |
| Renal impairment | No dose adjustment is required for patients with renal impairment. |
| Liver impairment | No dose adjustment is required for patients with hepatic impairment (Child-Pugh Class A, B, or C). |
| Pediatric use | Safety and efficacy have not been established in pediatric patients. |
| Geriatric use | No dose adjustment is necessary based on age; however, elderly patients may have higher sensitivity to QT prolongation. |
| 1st trimester | Risk of fetal harm based on mechanism of action (GnRH agonist). Avoid use during first trimester unless absolutely necessary. |
| 2nd trimester | May cause fetal harm if administered during second trimester due to potential hormonal effects. |
| 3rd trimester | Avoid use during third trimester as it may interfere with normal fetal development. |
Clinical note
Comprehensive clinical and safety monograph for CAMCEVI ETM (CAMCEVI ETM).
| Placental transfer | Leuprolide acetate is expected to cross the placenta based on its molecular weight and animal studies showing fetal effects. |
| Breastfeeding | Not recommended during breastfeeding due to potential for serious adverse effects in the nursing infant. Leuprolide may suppress lactation and is excreted in small amounts in breast milk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to leuprolide acetate or any component of the formulationPregnancy
| Precautions | Transient increase in serum testosterone during initial treatment may cause worsening of prostate cancer symptoms., Hypersensitivity reactions including anaphylaxis., Seizures have been reported., QT prolongation risk in patients with electrolyte abnormalities or on antiarrhythmic drugs. |
| Food/Dietary | Grapefruit juice may increase drug levels; avoid concurrent consumption. No other significant food interactions. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L5 - Contraindicated |
| Teratogenic Risk | CAMCEVI ETM (leuprolide) is an LHRH agonist. First trimester: Use is contraindicated as exposure can cause pregnancy loss or fetal abnormalities (androgen receptor-mediated effects). After conception, continued use increases risk of fetal harm, including spontaneous abortion and congenital anomalies (e.g., skeletal, cardiac). Second and third trimesters: Not indicated for use; if inadvertently used, risk of fetal growth restriction, oligohydramnios and other adverse outcomes due to continued hormonal suppression. Overall, use during pregnancy is contraindicated. |
| Fetal Monitoring | If exposure occurs in pregnancy, perform serial fetal ultrasonography to assess growth, anatomy, and amniotic fluid volume. Monitor pregnancy for signs of spontaneous abortion. Maternal monitoring includes serial serum LH, FSH, and E2 levels to confirm pharmacodynamic effect. Assess bone mineral density if treatment exceeds 6 months. |
| Fertility Effects | CAMCEVI ETM initially stimulates LH and FSH, then suppresses gonadotropins, leading to decreased estradiol/testosterone. In women, this may result in amenorrhea, ovulatory dysfunction, and temporary infertility. In men, reduced spermatogenesis and libido. Effects are generally reversible upon discontinuation; time to recovery varies but may take months. Long-term use may delay return of fertility. |
| CAMCEVI ETM (leuprolide) is an injectable GnRH agonist. Monitor for initial testosterone flare in prostate cancer patients; consider antiandrogen coverage. Do not use in pregnancy. Screen for pituitary apoplexy risk. Adjust dose in hepatic impairment. May cause QT prolongation; monitor electrolytes and ECG. |
| Patient Advice | Report new or worsening bone pain, difficulty urinating, or blood in urine. · Not for use in women who are or may become pregnant. · May cause hot flashes, decreased libido, erectile dysfunction, and mood changes. · Do not discontinue without consulting doctor. · Keep injections on schedule to maintain drug levels. · Inform doctor of all medications, especially antiarrhythmics and corticosteroids. |